P-162 Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer

Abstract

Conclusion:Patients who received the CAPOX-based perioperative regimen showed favorable survival. CAPOX might represent an option for patients eligible for perioperative chemotherapy. A prospective randomized study is ongoing to confirm these results.Legal entity responsible for the study: The author.